Shopping Cart

Remove All
Your shopping cart is currently empty

Metabolism

Acetyl-CoA Carboxylase

Amino Acids and Derivatives

Angiotensin-converting Enzyme (ACE)

Endogenous Metabolite

Glutathione Peroxidase

(40)

Glyoxalase

(2)

HIF/HIF Prolyl-Hydroxylase

Indoleamine 2,3-Dioxygenase (IDO)

(33)

Isocitrate Dehydrogenase (IDH)

Mitochondrial Metabolism

(94)

N-Acetylglucosaminyltransferase

Procollagen C Proteinase

(1)

Prolyl Endopeptidase (PREP)

Reactive Oxygen Species

Serine/threonin kinase

(46)

Stearoyl-CoA Desaturase (SCD)

SGK

Serine/threonine-protein kinases SGK represent a kinase subfamily with orthologs found across animal clades and in yeast (compare Treefam family TF320906). In most vertebrates, including humans, there are three isoforms encoded by the genes SGK1, SGK2, and SGK3. The name Serum/glucocorticoid-regulated kinase refers to the first cloning of a SGK family member from a cDNA library screen for genes upregulated by the glucocorticoid dexamethasone in a rat mammary epithelial tumor cell line. The first human family member (human SGK1) was cloned in a screen of hepatocellular genes regulated in response to cellular hydration or swelling.

Filter HomeSignaling PathwaysMetabolismSGK

Ro-3306

T2356872573-93-8

RO-3306 is a selectivity ATP-competitive CDK1 inhibitor (Ki: 20 nM). The selectivity of RO-3306 for CDK1 is >15-fold higher than a diverse panel of human kinases.

30 €

In Stock

Size

QTY

Cited

BN201

T146931361200-34-1

BN201 (OCS-05) is a drug with neuroprotective and myelin repair effects, which acts mainly by activating serum glucocorticoid kinase-2 (SGK2), which in turn activates the FOXO3 pathway to promote neuronal survival and myelin repair. It is mainly used for the treatment of inflammatory neurological diseases such as multiple sclerosis (MS) and experimental autoimmune encephalomyelitis (EAE).BN201 is able to regulate multiple kinases in the insulin growth factor 1 (IGF1) pathway and cross the blood-brain barrier.

278 €

In Stock

Size

QTY

GSK 650394

T2622890842-28-1

GSK 650394 is an inhibitor of serum- and glucocorticoid-regulated kinases (SGK) that inhibits SGK1 and SGK2 (IC50=62 103 nM). GSK 650394 has antitumor activity and also inhibits osteoclast differentiation and prevents bone loss.

32 €

In Stock

Size

QTY

URMC-099

T60571229582-33-5

URMC-099 is an orally bioavailable, brain penetrant MLK inhibitor (IC50: 19 42 14 150 nM, for MLK1 MLK2 MLK3 DLK), and also inhibits LRRK2 activity (IC50: 11 nM).

49 €

In Stock

Size

QTY

AT13148

T24821056901-62-2

AT13148 is an oral-active and ATP-competitive, multi-AGC kinase inhibitor for Akt1 2 3, p70S6K, PKA, and ROCKI II.

38 €

In Stock

Size

QTY

EMD638683

T66351181770-72-8

EMD638683,a novel SGK inhibitor with antihypertensive potency(with an IC50 of 3 μM).

84 €

In Stock

Size

QTY

SGK1-IN-4

T99771628048-93-0

SGK1-IN-4 is a selective inhibitor of SGK1 and can be used in studies about osteoarthritis.

107 €

In Stock

Size

QTY

SI-113

T95891392816-46-4

SI-113 is a potent and selective inhibitor of SGK1, a serine threonine protein kinase, that modulates several oncogenic signaling cascades.

36 €

In Stock

Size

QTY

Cited

BRD7389

T14779376382-11-5

BRD7389 is an inhibitor of RSK family kinase with IC50s of 1.5 μM, 2.4 μM, and 1.2 μM for RSK1, RSK2, and RSK3, respectively.

27 €

In Stock

Size

QTY

Cited

CKI-7

T199131177141-67-1

CKI-7 is a potent, ATP-competitive inhibitor of casein kinase 1 (CK1; IC50: 6 μM; Ki: 8.5 μM) and a selective Cdc7 kinase inhibitor. It also inhibits SGK, ribosomal S6 kinase-1 (S6K1), and MSK1.

110 €

In Stock

Size

QTY

PROTAC SGK3 degrader-1

T138472381320-35-8

PROTAC SGK3 degrader-1 (SGK3-PROTAC1) is a PROTAC coupler that targets SGK3 and binds ligand to VH032 VHL, inducing degradation of endogenous SGK3. It inhibits GDC0941-induced proliferation of cancer cells. [5017-88-83-4]

455 €

Backorder

Size

QTY

PT109

T2012732059104-90-2

PT109 is a multikinase inhibitor that targets JNK and other kinases, playing a crucial role in anti-inflammatory, antioxidative, neurogenic, and synaptogenic processes. Specifically, PT109 inhibits JNK isoforms with the following IC50 values: JNK1 at 0.143 μM, JNK2 at 0.831 μM, and JNK3 at 0.285 μM. It also inhibits SGK isoforms (SGK1: IC50=1.34 μM; SGK2: IC50=5.6 μM; SGK3: IC50=26.4 μM) and ROCK2 (IC50=34 μM). Additionally, PT109 reprograms polymorphic glioblastoma multiforme (GBM) into oligodendroglia via the PTBP1 PKM1 2 pathway and alters the metabolic pattern of GBM to exhibit antiglioma activity.